

API Pipeline List

S.N.	API	Originator	Therapeutic Area	Salt / Polymorphism	DMF Status	Status
1	Ambrisentan	Abbott	Hypertension	Form M	CN & US & EU	Commercial
2	Tolvaptan	Otsuka	Antihyponatremia drugs	Same as RLD.	US & EU	Commercial
3	Amisulpride	Sanofi	Acute or chronic schizophrenia	Same as RLD.	Not available	Validation
4	Lurasidone	Dainippon Sumitomo	Schizophrenia and bipolar disorder	Hydrochloride	CN	Scale-up
5	Gabapentin	Pfizer	Herpes zoster neuralgia, antiepileptic	Form II	Not available	Scale-up
6	Carbidopa	MSD	antiparkinsonian	Monohydrate	Not available	Lab trial
7	Benserazide	Roche	Antiparkinsonian	Hydrochloride	Not available	Scale-up
8	Canagliflozin	Johnson & Johnson	Diabetes	Hemihydrate	US	Commercial
9	Dimethyl Fumarate	Biogen Idec	Multiple sclerosis (MS)	Form I	US	Commercial
10	Vortioxetine	Lundbeck	Anti-depression	Hydrobromide/Form β	US	Validation
11	Apremilast	Celgene	Psoriatic arthritis	Form B	US	Validation
12	Dapagliflozin	BMS & AstraZeneca	Diabetes	S-propylene glycol monohydrate	US	Validation
13	Empagliflozin	Boehringer Ingelheim	Diabetes	Form 1	US	Validation
14	Sugammadex sodium	Merck Sharp Dohme	Muscle relaxation antagonist	TBD	Not available	Scale-up
15	Brivaracetam	UCB	Anti-epileptic	Form I	Not available	Scale-up
16	Safinamide	Zambon	Antiparkinsonian	Methanesulfonate	US	Validation
17	Elagolix	AbbVie	Endometriosis	Sodium salt amorphous	Not available	Scale-up
18	Oseltamivir phosphate	Roche	Anti-influenza drug	Phosphate	Not available	Lab trial
19	Rocuronium bromide	Organon	Muscle relaxant	Bromide	CN & US & EU	Validation

Disclaimer: Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities.

API Pipeline List

S.N.	API	Originator	Therapeutic Area	Salt / Polymorphism	DMF Status	Status
20	Azelaic acid	Allergan	Acne	—	US	Validation
21	Lacosamide	UCB	Adjuvant treatment of partial epilepsy	Form A	Not available	Scale-up
22	Suvorexant	Merck Sharp Dohme	Insomnia	Form I	Not available	Scale-up
23	Venetoclax	AbbVie	Leukemia	TBD	Not available	Lab trial
24	Relugolix	Takeda	Prostate cancer, fibroids, endometriosis	TBD	Not available	Lab trial
25	Lemborexant	Eisai	Insomnia	TBD	Not available	Lab trial
26	Posaconazole	Merck	Antifungal drug	TBD	Not available	Lab trial
27	Upadacitinib	AbbVie	Rheumatoid arthritis	TBD	Not available	Lab trial
28	Linzagolix	Kissei	Uterine fibroids and endometriosis	TBD	Not available	Lab trial
29	Resmetirom	Madrigal	Non-alcoholic fatty liver disease	TBD	Not available	Lab trial
30	Filgotinib	Gilead	Rheumatoid arthritis	TBD	Not available	Lab trial
31	Vibegron	Urovant	Overactive bladder	TBD	Not available	Lab trial
32	Butylphthalide	CSPC	Stroke	TBD	Not available	Lab trial
33	Memantine hydrochloride	Merz	Antiparkinsonian	Hydrochloride	Not available	Validation
34	Tofacitinib	Pfizer	RA(rheumatoid arthritis)	Citrate/Form A	Not available	Scale-up
35	Rasagiline	Teva & Lundbeck	Antiparkinsonian	Methanesulfonate	Not available	Scale-up
36	Levomilnacipran	Pierre Fabre	Anti-depression	Hydrochloride	US	Validation
37	Brexipiprazole	Otsuka Pharma	Major depressive disorder, MDD	Anhydrous	US	Validation
38	Cariprazine	Actavis	Bipolar / schizophrenic	Hydrochloride	Not available	Scale-up

Disclaimer: Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities.